Search

Stanley Friedman

Examiner (ID: 12067)

Most Active Art Unit
1205
Art Unit(s)
1802, 1803, 2607, 1205
Total Applications
1808
Issued Applications
1509
Pending Applications
0
Abandoned Applications
299

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 19613243 [patent_doc_number] => 20240398923 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => SUBUNIT VACCINE DELIVERY PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES [patent_app_type] => utility [patent_app_number] => 18/661174 [patent_app_country] => US [patent_app_date] => 2024-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17996 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18661174 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/661174
SUBUNIT VACCINE DELIVERY PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES May 9, 2024 Abandoned
Array ( [id] => 19599509 [patent_doc_number] => 20240390389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => HETEROCYCLIC COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/634495 [patent_app_country] => US [patent_app_date] => 2024-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 150807 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18634495 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/634495
HETEROCYCLIC COMPOUNDS AND USES THEREOF Apr 11, 2024 Pending
Array ( [id] => 19402054 [patent_doc_number] => 20240285565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN THE TREATMENT OF DIABETES AND PRE-DIABETES [patent_app_type] => utility [patent_app_number] => 18/443583 [patent_app_country] => US [patent_app_date] => 2024-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9671 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18443583 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/443583
USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN THE TREATMENT OF DIABETES AND PRE-DIABETES Feb 15, 2024 Pending
Array ( [id] => 19065615 [patent_doc_number] => 20240100041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/531086 [patent_app_country] => US [patent_app_date] => 2023-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18531086 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/531086
COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES Dec 5, 2023 Pending
Array ( [id] => 18844441 [patent_doc_number] => 20230406845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => NOVEL POTASSIUM CHANNEL INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/239348 [patent_app_country] => US [patent_app_date] => 2023-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39399 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 270 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18239348 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/239348
Potassium channel inhibitors Aug 28, 2023 Issued
Array ( [id] => 18808668 [patent_doc_number] => 20230383002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLS [patent_app_type] => utility [patent_app_number] => 18/326826 [patent_app_country] => US [patent_app_date] => 2023-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5192 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18326826 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/326826
Humanized BCMA antibody and BCMA-CAR-T cells May 30, 2023 Issued
Array ( [id] => 18763998 [patent_doc_number] => 11814384 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-14 [patent_title] => Inhibtors of Raf kinases [patent_app_type] => utility [patent_app_number] => 18/164326 [patent_app_country] => US [patent_app_date] => 2023-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79879 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18164326 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/164326
Inhibtors of Raf kinases Feb 2, 2023 Issued
Array ( [id] => 18709115 [patent_doc_number] => 20230331718 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => COMPOSITIONS FOR MODULATING SPLICING [patent_app_type] => utility [patent_app_number] => 18/162085 [patent_app_country] => US [patent_app_date] => 2023-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30594 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18162085 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/162085
COMPOSITIONS FOR MODULATING SPLICING Jan 30, 2023 Pending
Array ( [id] => 19059022 [patent_doc_number] => 11938217 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate [patent_app_type] => utility [patent_app_number] => 18/098505 [patent_app_country] => US [patent_app_date] => 2023-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5986 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18098505 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/098505
Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate Jan 17, 2023 Issued
Array ( [id] => 19768397 [patent_doc_number] => 20250049823 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => MITOCHONDRIAL ATP INHIBITORS TARGETING THE GAMMA SUBUNIT PREVENT METASTASIS [patent_app_type] => utility [patent_app_number] => 18/722474 [patent_app_country] => US [patent_app_date] => 2022-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18722474 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/722474
MITOCHONDRIAL ATP INHIBITORS TARGETING THE GAMMA SUBUNIT PREVENT METASTASIS Dec 21, 2022 Pending
Array ( [id] => 19768339 [patent_doc_number] => 20250049765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => BICYCLO [3.2.0] HEPTANE BIS(AMIDE) RXFP1 AGONISTS [patent_app_type] => utility [patent_app_number] => 18/718484 [patent_app_country] => US [patent_app_date] => 2022-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15999 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 447 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18718484 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/718484
BICYCLO [3.2.0] HEPTANE BIS(AMIDE) RXFP1 AGONISTS Dec 13, 2022 Pending
Array ( [id] => 18374280 [patent_doc_number] => 20230149358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT [patent_app_type] => utility [patent_app_number] => 18/071724 [patent_app_country] => US [patent_app_date] => 2022-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18071724 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/071724
COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT Nov 29, 2022 Pending
Array ( [id] => 19754297 [patent_doc_number] => 20250042862 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-06 [patent_title] => AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/709473 [patent_app_country] => US [patent_app_date] => 2022-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22201 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18709473 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/709473
AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Nov 9, 2022 Pending
Array ( [id] => 18793890 [patent_doc_number] => 11827642 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-28 [patent_title] => Compositions useful for treating disorders related to KIT [patent_app_type] => utility [patent_app_number] => 17/983747 [patent_app_country] => US [patent_app_date] => 2022-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 24860 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17983747 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/983747
Compositions useful for treating disorders related to KIT Nov 8, 2022 Issued
Array ( [id] => 18916698 [patent_doc_number] => 11878968 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-23 [patent_title] => Aryl compounds and pharmaceutical compositions that modulate IKZF2 [patent_app_type] => utility [patent_app_number] => 18/052462 [patent_app_country] => US [patent_app_date] => 2022-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30843 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052462 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/052462
Aryl compounds and pharmaceutical compositions that modulate IKZF2 Nov 2, 2022 Issued
Array ( [id] => 18437482 [patent_doc_number] => 20230184777 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => DIAGNOSIS AND TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/046606 [patent_app_country] => US [patent_app_date] => 2022-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16732 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046606 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/046606
DIAGNOSIS AND TREATMENT OF CANCER Oct 13, 2022 Pending
Array ( [id] => 18384471 [patent_doc_number] => 11655240 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-05-23 [patent_title] => Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases [patent_app_type] => utility [patent_app_number] => 17/964389 [patent_app_country] => US [patent_app_date] => 2022-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 18555 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17964389 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/964389
Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases Oct 11, 2022 Issued
Array ( [id] => 19691203 [patent_doc_number] => 20250009748 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => COMBINATION THERAPY USING SUBSTITUTED PYRIMIDIN-4(3H)-ONES AND SOTORASIB [patent_app_type] => utility [patent_app_number] => 18/696931 [patent_app_country] => US [patent_app_date] => 2022-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38622 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -59 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18696931 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/696931
COMBINATION THERAPY USING SUBSTITUTED PYRIMIDIN-4(3H)-ONES AND SOTORASIB Sep 29, 2022 Pending
Array ( [id] => 18701291 [patent_doc_number] => 11787790 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Benzimidazole derivative having fluorine-containing substituent, preparation and application thereof [patent_app_type] => utility [patent_app_number] => 17/947260 [patent_app_country] => US [patent_app_date] => 2022-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4218 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 241 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17947260 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/947260
Benzimidazole derivative having fluorine-containing substituent, preparation and application thereof Sep 18, 2022 Issued
Array ( [id] => 18724411 [patent_doc_number] => 20230338569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => NaPi2b-TARGETED POLYMER ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF OVARIAN CANCER [patent_app_type] => utility [patent_app_number] => 17/930924 [patent_app_country] => US [patent_app_date] => 2022-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 277 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930924 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/930924
NaPi2b-TARGETED POLYMER ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF OVARIAN CANCER Sep 8, 2022 Abandoned
Menu